Project Description

RebioticsRx

At a glance

Established by Integra Holdings in 2018, Rebiotics Rx is developing novel liposomal antibiotics for antibiotic-resistant bacterial infections.
The platform was developed by Prof. Yechezkel Barenholtz, Prof.Amiram Goldblum and Dr.Ahuva Cern from the School of Pharmacy at the Hebrew University.

Market Potential

The global market for Infectious Diseases was estimated at $3.2 billion in 2017, with increasing market share and sales of novel antibiotics developed and marketed by major pharma companies.

Company Highlights

The lead product of Rebiotics Rx is a PEGylated Nanoliposomal-mupirocin formulation. Mupirocin has a unique mode of action, not shared by any other available antibiotic. It is active against pathogens defined as “urgent and serious threats” to public health, such as Neisseria gonorrhea, methicillin resistant Staphylococcus aureus (MRSA), and Streptococcus pneumonia. However, its short half-life in circulation prevents its parenteral use and limits it to topical one. Reformulation of mupirocin by the nanoliposomes increases substantially the systemic exposure to mupirocin and prolongs its half-life, thereby enabling the parenteral activity of mupirocin and practically resulting in a novel antibiotic with demonstrated efficacy in relevant animal models. The product is at advanced preclinical development.

Key Shareholders

Integra Holdings

Funding

Extensive business development activity is ongoing, to support further development of the technology

http://www.rebioticsrx.com/

More Companies